Wegovy (semaglutide) is an FDA-approved injectable medication for chronic weight management that costs over $1,350 per month at list price. Medicaid coverage for Wegovy depends entirely on your state’s program, and the rules differ dramatically across the country.
Some state Medicaid programs cover Wegovy and other GLP-1 medications for weight loss with prior authorization. Others exclude anti-obesity drugs entirely. Medicare covers Wegovy for cardiovascular risk reduction in eligible patients. Understanding your options is the first step toward accessing this treatment.
This guide explains how federal and state Medicaid rules interact, which states currently cover Wegovy, how prior authorization works, and what to do when coverage is denied. You will also find alternatives and savings programs that may help reduce out-of-pocket costs.
Does Medicaid Cover Wegovy?
Medicaid coverage for Wegovy varies by state and is not guaranteed at the federal level for weight loss alone. The federal government sets baseline Medicaid rules, but each state controls its own formulary and decides which drugs to cover for which indications.
Some states cover Wegovy for chronic weight management when patients meet clinical criteria such as a BMI of 30 or higher, or 27 with a weight-related comorbidity. Other states limit coverage to FDA-approved uses like cardiovascular risk reduction. Many states do not cover anti-obesity medications at all under their Medicaid programs.
Coverage is also affected by how the drug is prescribed. Wegovy prescribed on-label for weight management has a different coverage pathway than semaglutide (the same active ingredient) prescribed as Ozempic for Type 2 diabetes. Medicaid may cover the diabetes indication while rejecting the weight loss claim.
What Is Wegovy and How Does It Work?
Wegovy is a once-weekly injectable GLP-1 receptor agonist containing semaglutide at a 2.4 mg dose. GLP-1 stands for glucagon-like peptide-1, a hormone the gut releases after eating that signals fullness to the brain.
Wegovy slows gastric emptying, which means food stays in the stomach longer. That delay reduces hunger signals and lowers caloric intake without requiring willpower alone. Clinical trials showed patients lost an average of 15 percent of their body weight over 68 weeks on semaglutide 2.4 mg.
The FDA approved Wegovy in June 2021 for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as hypertension, Type 2 diabetes, or high cholesterol. In 2023, the FDA expanded approval to include cardiovascular risk reduction in adults with obesity or overweight and established cardiovascular disease.
Why Does Coverage Vary by State?
Medicaid is a joint federal-state program, and states have broad authority to design their own formularies and coverage policies. Federal law requires states to cover certain drug categories, but anti-obesity medications are not in the mandatory coverage list.
This means a state can legally exclude all weight loss drugs from Medicaid without violating federal requirements. Some states have chosen to cover GLP-1 medications as a public health investment, calculating that treating obesity reduces long-term costs from diabetes, heart disease, and joint replacements. Others cite budget constraints.
Federal guidance from the Centers for Medicare and Medicaid Services (CMS) periodically updates which drug categories states must cover. Advocacy groups are pushing for federal rules that would require all state Medicaid programs to cover anti-obesity medications, but no such mandate existed as of late 2026.
Which States Cover Wegovy Under Medicaid?
State-level Medicaid coverage for Wegovy is an evolving landscape with several states adding or expanding anti-obesity drug coverage in 2025 and 2026. No single federal list tracks every state’s current policy in real time.
States that have publicly committed to covering GLP-1 medications for obesity under Medicaid include Illinois, California, New York, and Washington. These states typically require prior authorization and impose clinical criteria such as documented BMI thresholds and failed prior weight loss attempts.
States with restricted or no coverage for anti-obesity drugs under Medicaid include Texas, Florida, and Georgia, though policies can change with each legislative session or state budget cycle. The best source for your specific state is your state Medicaid agency’s published formulary or a call to your state’s Medicaid helpline.
State Coverage Overview:
| State Group | Coverage Status | Typical Requirement |
| California, Illinois, New York | Covers with PA | BMI 30+ or 27+ with comorbidity |
| Washington, Oregon, Colorado | Covers with PA | Prior weight loss program required |
| Texas, Florida, Georgia | Limited or no coverage | Cardiovascular indication only |
| Most remaining states | Varies by cycle | Check state formulary directly |
What Are the Common Requirements for Coverage?
Most states that cover Wegovy under Medicaid require prior authorization and impose several clinical criteria before approving the drug. These criteria protect the program from off-label use and ensure patients most likely to benefit receive coverage.
Common requirements include a documented BMI of 30 or above, or 27 or above with at least one qualifying comorbidity such as Type 2 diabetes, hypertension, or obstructive sleep apnea. Prescribers typically must document that the patient has tried and failed at least one prior medically supervised weight loss program or lifestyle intervention.
A diagnosis of obesity (ICD-10 code E66) must appear on the prior authorization request. Some states also require the prescriber to be a licensed physician or specialist rather than an advanced practice provider. Renewal authorizations often require evidence of at least 5 percent body weight loss within the first six months of treatment.
Common Prior Authorization Criteria:
- BMI of 30 or above (or 27 with comorbidity)
- Documented failed lifestyle intervention
- Formal obesity diagnosis (ICD-10 E66)
- Licensed physician prescriber
- Six-month weight loss proof for renewal
What Other Weight Loss Drugs Does Medicaid Cover?
Beyond Wegovy, several other medications may qualify for Medicaid coverage depending on state formulary decisions and the FDA indication used. Each drug has its own coverage rules and patient criteria.
Ozempic (semaglutide 1 mg) is FDA-approved for Type 2 diabetes management. Medicaid programs in almost every state cover Ozempic for diabetes, even when the same drug class (semaglutide) is excluded for weight loss. Patients with both obesity and Type 2 diabetes sometimes access semaglutide through the diabetes coverage pathway.
Saxenda (liraglutide) is another injectable GLP-1 approved specifically for weight management. Some states that cover weight loss drugs include Saxenda on their formularies alongside or instead of Wegovy. Qsymia, Contrave, and phentermine are older oral anti-obesity medications that some state Medicaid programs cover at lower cost tiers.
How Does Prior Authorization Work for Wegovy?
Prior authorization (PA) is a formal approval process where the prescriber submits clinical documentation to Medicaid before the pharmacy dispenses the medication. Without PA approval, the pharmacy will reject the claim.
The prescriber’s office typically submits the PA request electronically through the state Medicaid portal or by fax. The request must include the patient’s diagnosis codes, clinical notes documenting BMI and comorbidities, records of prior weight loss attempts, and the specific drug and dosage requested.
States are required to respond to standard PA requests within two business days. For urgent medical situations, the response window drops to 24 hours. If the prescriber submits incomplete documentation, the clock resets when the missing information arrives.
What Criteria Do States Use for Prior Authorization?
States evaluate PA requests against a clinical policy document called a coverage determination policy or drug coverage criteria sheet. Knowing these criteria before submission dramatically improves approval rates.
Most states require the diagnosis of obesity to be the primary indication on the PA form, not just a secondary condition. The prescriber must confirm the patient has received counseling on diet and physical activity as adjunct therapy. Some states specify that the patient must not have a contraindication such as a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
A peer-reviewed clinical note or a letter of medical necessity from the prescriber strengthens the PA request. Our coaches at Eat Proteins have seen cases where adding a detailed weight history and a timeline of prior interventions turned a denial into an approval on the second attempt.
How Long Does Prior Authorization Take?
Standard prior authorization for Wegovy takes two to seven business days in most state Medicaid programs, though complex cases can take two to three weeks. Urgency designation can cut that to 24 hours when medically justified.
Delays often occur because the prescriber’s office submits incomplete documentation, the pharmacy submits to the wrong PA unit, or the clinical notes do not clearly map to the state’s coverage criteria. Coordinating between the prescriber and the pharmacy benefits manager speeds up the process.
Patients can check PA status by calling the Medicaid member services number on their card or by logging into their state’s Medicaid beneficiary portal. Some states also allow the prescriber’s office to track PA status through the electronic submission system.
What If Medicaid Denies Coverage for Wegovy?
A Medicaid denial for Wegovy is not final, and patients have the legal right to appeal through a formal grievance process. Federal law requires Medicaid programs to have an appeal mechanism for all coverage denials.
The denial letter must explain the specific reason coverage was refused. Common reasons include insufficient clinical documentation, a BMI that does not meet the threshold, no documented prior weight loss attempt, or the drug simply not being on the state formulary. Knowing the exact denial reason is the first step to building a successful appeal.
Ready to speed things up? Get a proven weight loss plan built around the same principles that make Wegovy effective, so you have a documented history of supervised weight loss to support your coverage case.
How Do You Appeal a Medicaid Denial?
To appeal a Medicaid denial, the patient or prescriber must file a written appeal within the timeframe stated in the denial letter, typically 30 to 90 days. Missing the deadline forfeits the right to appeal that denial.
The appeal package should include the original denial letter, a letter of medical necessity from the prescriber, clinical notes documenting the patient’s weight history and prior interventions, peer-reviewed research supporting Wegovy’s efficacy in the patient’s clinical profile, and any relevant lab results.
A peer-to-peer review is a separate option where the prescriber calls the Medicaid medical director directly to discuss the case. This step often resolves denials faster than the formal written appeal. If the internal appeal fails, patients can request an independent external review through the state’s designated review organization.
Steps to Appeal a Wegovy Denial:
- Read the denial letter and identify the exact reason for rejection.
- Gather updated clinical notes, BMI documentation, and prior treatment records.
- Have the prescriber write a detailed letter of medical necessity.
- File the written appeal before the stated deadline.
- Request a peer-to-peer review between the prescriber and the Medicaid medical director.
- If the internal appeal fails, request an external independent review.
What Alternatives Exist When Medicaid Won’t Cover Wegovy?
When Medicaid denies coverage, several alternatives can make Wegovy or similar medications accessible at a reduced cost. Novo Nordisk, Wegovy’s manufacturer, operates a patient assistance program through NovoCare Pharmacy.
The NovoCare savings offer allows eligible patients without insurance to access Wegovy at a significantly reduced monthly cost. Eligibility is based on household income relative to the federal poverty level. Patients can apply directly at the NovoCare website with proof of income.
Compounding pharmacies have also produced semaglutide formulations during shortage periods, though the FDA has warned about quality and dosing consistency issues with compounded versions. Saxenda (liraglutide) and older oral anti-obesity drugs may be available on state formularies when Wegovy is not, and switching drugs may provide a path to coverage.
Does Medicare Cover Wegovy?
Medicare covers Wegovy under Part D for patients prescribed it for cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight. This indication was FDA-approved in 2023 and opened a new coverage path for Medicare beneficiaries.
The Medicare GLP-1 Bridge Program, launching nationwide on July 1, 2026, offers eligible Medicare patients Wegovy at $50 per month. The program covers all doses and formulations of Wegovy injection and Wegovy pill for weight management through the end of 2027. Eligibility criteria are determined by the Centers for Medicare and Medicaid Services.
Medicare does not currently cover Wegovy for weight loss alone without a qualifying cardiovascular disease diagnosis. Patients who do not have established cardiovascular disease must rely on their state Medicaid program, supplemental insurance, or manufacturer savings programs for weight management coverage.
Who Qualifies for Medicare Wegovy Coverage?
To qualify for Medicare Wegovy coverage, a patient must have established cardiovascular disease, defined as prior heart attack, stroke, or symptomatic peripheral artery disease, plus a BMI of 27 or above.
Part D prescription drug plans must cover Wegovy for this cardiovascular indication. A co-pay will apply depending on the specific plan’s formulary tier. Patients who also qualify for Medicaid (dual eligibles) may have their co-pay reduced or eliminated through state Medicaid low-income subsidy programs.
For Medicare beneficiaries who do not have cardiovascular disease but do have obesity, the $50 per month GLP-1 Bridge Program is the most accessible option starting July 2026. The prescriber must submit a valid prescription, and patients enroll directly through the NovoCare platform to access bridge program pricing.
How Much Does Wegovy Cost Without Insurance?
Wegovy’s list price is approximately $1,350 per month, making it one of the most expensive chronic disease medications available without insurance coverage. The retail price varies by pharmacy and may differ from the manufacturer’s published list price.
Patients who pay out of pocket for the full year of a recommended treatment course face costs exceeding $16,000. This price point places Wegovy far beyond the reach of most Medicaid-eligible patients, which is why coverage advocacy and prior authorization support are so critical.
Pharmacy discount cards such as GoodRx and RxSaver can reduce the retail price, but the discounts on branded biologics like Wegovy are typically modest compared with generic medications. Splitting a prescription across multiple pharmacies to find the lowest price is another option some patients use while awaiting coverage decisions.
What Savings Programs Are Available for Wegovy?
Novo Nordisk offers a savings card for commercially insured patients that caps out-of-pocket costs at $25 per month for eligible prescriptions. Medicaid patients are not eligible for this commercial savings card, but separate income-based assistance exists.
The NovoCare Patient Assistance Program provides free Wegovy to patients who meet income eligibility requirements, typically at or below 400 percent of the federal poverty level with no qualifying insurance. Applications require proof of income, a valid prescription, and prescriber enrollment in the program.
State pharmaceutical assistance programs (SPAPs) in certain states provide supplemental drug coverage for low-income residents. These programs sometimes cover drugs excluded from Medicaid formularies. Checking with your state health department or a licensed social worker can identify SPAP eligibility in your state.
Available Savings Options:
- NovoCare Savings Card (commercially insured, $25/month cap)
- NovoCare Patient Assistance Program (income-based, free drug)
- Medicare GLP-1 Bridge Program ($50/month, July 2026 onward)
- State pharmaceutical assistance programs (vary by state)
- Pharmacy discount cards (modest savings on branded drugs)
Want Your Free Weight Loss Plan from Eat Proteins?
You now have the full picture on Medicaid and Wegovy. But coverage is only one piece of the puzzle. The nutritionists at Eat Proteins built a free meal plan that mirrors the dietary principles proven to work alongside GLP-1 medications, high protein, lower calorie density, and structured eating windows that reduce hunger without relying on a drug alone.
Don’t wait for an insurance approval to start moving in the right direction. Get the exact framework our team uses with clients who are navigating coverage gaps. It’s free, it’s built on real science, and it gives you something concrete to start today.